Tyra Biosciences Stock Alpha and Beta Analysis
| TYRA Stock | USD 14.71 0.06 0.41% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Tyra Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Tyra Biosciences over a specified time horizon. Remember, high Tyra Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Tyra Biosciences' market risk premium analysis include:
Beta 0.76 | Alpha (0.97) | Risk 3.03 | Sharpe Ratio (0.05) | Expected Return (0.14) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Tyra |
Tyra Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Tyra Biosciences market risk premium is the additional return an investor will receive from holding Tyra Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Tyra Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Tyra Biosciences' performance over market.| α | -0.97 | β | 0.76 |
Tyra Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Tyra Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Tyra Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Tyra Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Tyra Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Tyra Biosciences shares will generate the highest return on investment. By understating and applying Tyra Biosciences stock market price indicators, traders can identify Tyra Biosciences position entry and exit signals to maximize returns.
Tyra Biosciences Return and Market Media
The median price of Tyra Biosciences for the period between Sat, Nov 2, 2024 and Fri, Jan 31, 2025 is 15.83 with a coefficient of variation of 12.51. The daily time series for the period is distributed with a sample standard deviation of 2.0, arithmetic mean of 15.95, and mean deviation of 0.96. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 10750 shares by Kjellson Nina S of Tyra Biosciences at 16.4596 subject to Rule 16b-3 | 10/31/2024 |
2 | Disposition of 116 shares by Kjellson Nina S of Tyra Biosciences at 17.006 subject to Rule 16b-3 | 11/04/2024 |
3 | Disposition of 1126 shares by Kjellson Nina S of Tyra Biosciences at 16.7683 subject to Rule 16b-3 | 11/05/2024 |
4 | Disposition of 5635 shares by Kjellson Nina S of Tyra Biosciences at 17.1755 subject to Rule 16b-3 | 11/06/2024 |
5 | Disposition of 2371 shares by Kjellson Nina S of Tyra Biosciences at 17.3181 subject to Rule 16b-3 | 11/07/2024 |
6 | Tyra Biosciences Price Target Cut to 30.00 by Analysts at HC Wainwright | 11/11/2024 |
7 | RA Capital Management, L.P. Increases Stake in Tyra Biosciences Inc - GuruFocus.com | 11/14/2024 |
8 | Disposition of 566 shares by Kjellson Nina S of Tyra Biosciences at 16.8386 subject to Rule 16b-3 | 11/25/2024 |
9 | Were Not Very Worried About Tyra Biosciences Cash Burn Rate | 12/11/2024 |
10 | Disposition of tradable shares by Moran Susan of Tyra Biosciences subject to Rule 16b-3 | 12/17/2024 |
11 | Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer | 01/10/2025 |
12 | Disposition of 835 shares by Kjellson Nina S of Tyra Biosciences at 16.287 subject to Rule 16b-3 | 01/16/2025 |
13 | Disposition of 461 shares by Kjellson Nina S of Tyra Biosciences at 16.4001 subject to Rule 16b-3 | 01/17/2025 |
14 | Disposition of 93 shares by Kjellson Nina S of Tyra Biosciences at 16.3626 subject to Rule 16b-3 | 01/21/2025 |
15 | Disposition of 4825 shares by Kjellson Nina S of Tyra Biosciences at 16.2624 subject to Rule 16b-3 | 01/23/2025 |
16 | Tyra Biosciences Insider Ups Holding By 284 percent During Year - Simply Wall St | 01/30/2025 |
About Tyra Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Tyra or other stocks. Alpha measures the amount that position in Tyra Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Tyra Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Tyra Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tyra Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Tyra Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Tyra Biosciences. Please utilize our Beneish M Score to check the likelihood of Tyra Biosciences' management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Tyra Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Tyra Biosciences Backtesting, Tyra Biosciences Valuation, Tyra Biosciences Correlation, Tyra Biosciences Hype Analysis, Tyra Biosciences Volatility, Tyra Biosciences History and analyze Tyra Biosciences Performance. For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Tyra Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.